Search

Author/Creator Nagrial, A

1. 414PDPhase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (23rd October 2018)

Authors:
Cho, B C; Perets, R; Bar, J; Ahn, M-J; Kim, D-W; Yoh, K; Nagrial, A; Spigel, D R; Lee, D H; Gutierrez, M; Kotasek, D; Siddiqi, S; Chain, A; Butts, B D; Zhang, Y; Li, X; Cyrus, J; Tse, A; Altura, R A; Rasco, D
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 98P Results from a phase I study of MK-1308 (anti–CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer. (15th December 2019)

Authors:
Cho, B C; Yoh, K; Bar, J; Nagrial, A; Spigel, D R; Gutierrez, M; Kim, D-W; Kotasek, D; Rasco, D; Niu, J; Satouchi, M; Ahn, M-J; Lee, D H; Maurice-Dror, C; Siddiqi, S; Li, X; Cyrus, J; Altura, R A; Perets, R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis. (15th December 2019)

Authors:
Paz-Ares, L; Ciuleanu, T E; Yu, X; Salman, P; Pluzanski, A; Nagrial, A; Havel, L; Kowalyszyn, R; Audigier-Valette, C; Wu, Y-L; Borghaei, H; Hellmann, M D; Brahmer, J; Reck, M; Ramalingam, S; Zhang, L; Bhagavatheeswaran, P; Nathan, F E; O'Byrne, K J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search